MedPath

Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study

Phase 2
Completed
Conditions
Pterygium
Interventions
Registration Number
NCT02342392
Lead Sponsor
Universiti Sains Malaysia
Brief Summary

The purpose of this study is to evaluate the pterygium vascularity and size before and after intralesional ranibizumab injection and to evaluate its recurrence rate following pterygium excision surgery.

Detailed Description

The purpose of this study is to:

1. Compare the vascularity of primary pterygium before and 1 week after intralesional ranibizumab (0.3 mg/0.03 mL) injection.

2. Compare the size of primary pterygium before and 1 week after intralesional ranibizumab (0.3 mg/0.03 mL) injection.

3. Compare the recurrence rate at 1 year after pterygium excision surgery between the group with and without intralesional ranibizumab injection.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
36
Inclusion Criteria
  • All patients with primary pterygium.
  • Grade T3 (fleshy) pterygium.
Exclusion Criteria
  • Patients with other ocular surface disorders.
  • Previous ocular surgery or trauma.
  • History of systemic thromboembolic event.
  • Pregnant women and lactating mother.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
treatment groupranibizumabintralesional ranibizumab injected
Primary Outcome Measures
NameTimeMethod
pterygium recurrence1 year

pterygium recurrence is defined as true recurrence with a fibrovascular tissue invading the cornea (grade 4 lesion)

Secondary Outcome Measures
NameTimeMethod
pterygium vessel area1 week

Pterygium vesel area is defined as the as the ration of pixels occupied by the vessels within the pterygium area in percentage.

corneal pterygium area1 week

Corneal pterygium area is defined as the as the ration of pixels occupied by the pterygium within the cornea area in percentage.

© Copyright 2025. All Rights Reserved by MedPath